ISIS 3521 clinical trials
Also written ISIS 3521 and LY900003.
How each study uses ISIS 3521 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 1998 (2)
| Year | Studies |
|---|---|
| 1998 | 2 |
| 2000 | 1 |
| 2002 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Eli Lilly and Company (2) · Eastern Cooperative Oncology Group (1) · Ionis Pharmaceuticals, Inc. (1) · European Organisation for Research and Treatment of Cancer - EORTC (1)
Often tested with
Tested in the same studies.
Carboplatin (2) · ISIS 5132 (1) · Paclitaxel (1) · Gemcitabine (1)
Studies
Open first, then newest update. How each study uses ISIS 3521 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Chemotherapy in Treating Women With Previously Treated Metastatic Breast CancerCompletedPhase 2Eastern Cooperative Oncology GroupNCT00003236Written as ISIS 3521How we know
- Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung CancerCompletedPhase 3Ionis Pharmaceuticals, Inc.NCT00017407Written as ISIS 3521How we know
- ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic MelanomaCompletedPhase 2European Organisation for Research and Treatment of Cancer - EORTCNCT00003989Written as ISIS 3521How we know
- A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung CancerCompletedPhase 3Eli Lilly and CompanyNCT00034268Written as LY900003How we know
- A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer.CompletedPhase 2Eli Lilly and CompanyNCT00042679Written as LY900003How we know